{"entity":{"id":"nct02734004","kind":"trial","name":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","aka":["MEDIOLA"],"tldr":"A phase 1/2 trial of Olaparib and Bevacizumab in ovarian cancer, small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.","summary":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT02734004 by AstraZeneca, with 264 participants enrolled, started 2016-03-17 and due to reach its primary completion in 2021-09-17. Interventions recorded: Olaparib, MEDI4736 and Bevacizumab. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02734004","url":"https://clinicaltrials.gov/study/NCT02734004"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","sclc","gastric"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["olaparib","bevacizumab"],"companies":["astrazeneca","iqvia"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct02734004-lancet-oncol-2020"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02734004","phase":"1/2","setting":"A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors","sponsor":"AstraZeneca","started":"2016-03-17","startedType":"actual","yearReported":2023,"enrolled":264,"enrolledBasis":"registry","outcomes":[{"endpoint":"Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12","primary":true,"unit":"%","arms":[{"name":"Initial Stage: Small Cell Lung Cancer","n":38,"value":28.9,"note":"Figures from the ClinicalTrials.gov results section (first posted 2023-10-13), not from a publication"},{"name":"Initial Stage: Breast Cancer","n":30,"value":80},{"name":"Initial Stage: Ovarian Cancer","n":32,"value":81.3},{"name":"Initial Stage: Gastric Cancer","n":39,"value":25.6}],"source":"https://clinicaltrials.gov/study/NCT02734004?tab=results"},{"endpoint":"Second Stage Cohort: Objective Response Rate (ORR)","primary":true,"unit":"%","arms":[{"name":"Second Stage: Ovarian Cancer Expansion","n":51,"value":92.2,"note":"95% CI 81.12 to 97.82; Figures from the ClinicalTrials.gov results section (first posted 2023-10-13), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT02734004?tab=results"},{"endpoint":"Second Stage Cohorts: DCR at Week 24","primary":true,"unit":"%","arms":[{"name":"Second Stage: Ovarian Cancer Triplet","n":31,"value":74.2,"note":"Figures from the ClinicalTrials.gov results section (first posted 2023-10-13), not from a publication"},{"name":"Second Stage: Ovarian Cancer Doublet","n":32,"value":28.1}],"source":"https://clinicaltrials.gov/study/NCT02734004?tab=results"}]},"route":"/trials/nct02734004/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"iqvia","kind":"company","name":"IQVIA","route":"/companies/iqvia/"}],"paper":[{"id":"paper-nct02734004-lancet-oncol-2020","kind":"paper","name":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study","route":"/key-papers/paper-nct02734004-lancet-oncol-2020/"}]}}